Evidence map›Paper›PMID 34458390›Full record

ArticleOpen forum infectious diseases2021

Engaging People Who Inject Drugs Living With HIV in Antiretroviral Treatment and Medication for Opioid Use Disorder: Extended Follow-up of HIV Prevention Trials Network (HPTN) 074.

Kathryn E Lancaster, Katie R Mollan, Brett S Hanscom, Bonnie E Shook-Sa, Tran V Ha, Kostyantyn Dumchev, Zubairi Djoerban, Scott M Rose, Carl A Latkin, David S Metzger and 16 more

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 11 institutions in 4 countries.

Kathryn E LancasterDivision of Epidemiology, College of Public Health, The Ohio State University, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0003-2389-6973
Katie R MollanCenter for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Brett S HanscomStatistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Bonnie E Shook-SaCenter for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Tran V HaGillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Kostyantyn DumchevUkrainian Institute on Public Health Policy, Kyiv, Ukraine.
Zubairi DjoerbanFaculty of Medicine, University of Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
Scott M RoseScience Facilitation Department, FHI 360, Durham, North Carolina, USA.
Carl A LatkinDepartment of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
David S MetzgerHIV Prevention Research Division, Department of Psychiatry, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Vivian F GoGillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Sergii DvoriakAcademy of Labor, Social Relations and Tourism, Kyiv, Ukraine.
Sarah A ReifeisCenter for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Estelle M Piwowar-ManningDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Paul RichardsonDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Michael G HudgensCenter for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Erica L HamiltonScience Facilitation Department, FHI 360, Durham, North Carolina, USA.
Susan H EshlemanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Hepa SusamiFaculty of Medicine, University of Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
Viet Anh ChuUNC Vietnam, Hanoi, Vietnam.
Samsuridjal DjauziFaculty of Medicine, University of Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
Tetiana KiriazovaUkrainian Institute on Public Health Policy, Kyiv, Ukraine.
Do Thi NhanVietnam Administration of HIV/AIDS Control, Hanoi, Vietnam.
David N BurnsDivision of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
William C MillerDivision of Epidemiology, College of Public Health, The Ohio State University, Columbus, Ohio, USA.
Irving F HoffmanDivision of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
University of North Carolina at Chapel Hill · USJohns Hopkins University · USUniversity of Indonesia · IDFamily Health International 360 · USThe Ohio State University · USUkrainian Institute of Public Health Policy · UAAcademy of Labour Social Relations and Tourism · UAFred Hutch Cancer Center · USMinistry of Health · VNNational Institutes of Health · USUniversity of Pennsylvania · US

Funding

LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI Sinead Delany-Moretlwe, RAPHAEL J LANDOVITZ · 2011 to 2026
$779.5M
SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ROBERT GROSS · 1999 to 2026
$78.6M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
University of Pennsylvania HIV Clinical Trials UnitUM1AI069534 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Ian Frank, PABLO TEBAS · 2012 to 2026
$33.0M
NIAID NIH HHS P30 AI045008NIAID NIH HHS P30 AI050410NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068619NIAID NIH HHS UM1 AI069534
6 · The paper itself

Abstract

backgroundPeople who inject drugs (PWID) living with HIV experience inadequate access to antiretroviral treatment (ART) and medication for opioid use disorders (MOUD). HPTN 074 showed that an integrated intervention increased ART use and viral suppression over 52 weeks. To examine durability of ART, MOUD, and HIV viral suppression, participants could re-enroll for an extended follow-up period, during which standard-of-care (SOC) participants in need of support were offered the intervention.

methodsParticipants were recruited from Ukraine, Indonesia and Vietnam and randomly allocated 3:1 to SOC or intervention. Eligibility criteria included: HIV-positive; active injection drug use; 18-60 years of age; ≥1 HIV-uninfected injection partner; and viral load ≥1,000 copies/mL. Re-enrollment was offered to all available intervention and SOC arm participants, and SOC participants in need of support (off-ART or off-MOUD) were offered the intervention.

resultsThe intervention continuation group re-enrolled 89 participants, and from week 52 to 104, viral suppression (<40 copies/mL) declined from 41% to 29% (estimated 9.4% decrease per year, 95% CI -17.0%; -1.8%). The in need of support group re-enrolled 94 participants and had increased ART (re-enrollment: 55%, week 26: 69%) and MOUD (re-enrollment: 16%, week 26: 25%) use, and viral suppression (re-enrollment: 40%, week 26: 49%).

conclusionsViral suppression declined in year 2 for those who initially received the HPTN 074 intervention and improved maintenance support is warranted. Viral suppression and MOUD increased among in need participants who received intervention during the study extension. Continued efforts are needed for widespread implementation of this scalable, integrated intervention.

Indexed as

antiretroviral therapyHIV infectioninjection drug usemethadone/therapeutic useviral load

Identifiers

PMID34458390
PMCPMC8391093
OpenAlexW3166312995

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.